This article is more than 5 years old. Information may no longer be current.

Empagliflozin for CKD trial launches

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Boehringer Ingelheim and Eli Lilly announced plans to conduct a trial of empagliflozin, an SGLT2 inhibitor, for the treatment of chronic kidney disease in adults with and without type 2 diabetes, according to a company press release.

In the EMPA-REG Outcome trial, empagliflozin (Jardiance, Boehringer Ingelheim/Lilly) was associated with a reduction in cardiovascular death and also reduced the risk for new-onset or worsening of kidney disease by 39% in adults with type 2 diabetes and cardiovascular disease. In December, the FDA approved an indication to reduce the risk for cardiovascular death

“Based on the [CV] and renal results of the EMPA-REG Outcome trial, we, along with Boehringer Ingelheim, look forward to starting this new trial to gather evidence in support of a potential new indication for empagliflozin in people with [CKD],” said Jeff Emmick, MD, PhD, vice president of product development at Lilly Diabetes, said in the release.